Product Information
ATOMOXETINE HCL 18 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.3818 per EA under NDC 00093354356. Its NADAC has been published 476 times since Aug 23, 2017.
FDA first approved this application on May 30, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
18 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093354356
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATOMOXETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079022FDA Approved
5/30/2017
TE Code
AB
On Market Since
5/30/2017
Pharmacological Classes
Price Statistics
The NADAC for ATOMOXETINE HCL 18 MG CAPSULE has been published 476 times since Aug 23, 2017, and over the history we have for it it has declined 90.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3818 per EA |
|---|---|
| All-time high | $4.0610 (Sep 13, 2017) |
| All-time low | $0.3818 (Sep 23, 2026) |
| 52-week high | $0.5340 |
| 52-week low | $0.3818 |
| Median price | $1.0614 |
| Average price | $1.4055 |
| Largest weekly change | -33.1% (Sep 20, 2023) |
| Weeks tracked | 476 |
| Tracking since | Aug 23, 2017 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atomoxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATOMOXETINE HCL 18 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ATOMOXETINE HCL 18 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.3818 per EA (NDC 00093354356), effective Sep 30, 2026.
How has the price of ATOMOXETINE HCL 18 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ATOMOXETINE HCL 18 MG CAPSULE has declined 90.6%. It has been tracked across 476 weekly CMS publications since Aug 23, 2017.
What are the highest and lowest recorded NADAC prices for ATOMOXETINE HCL 18 MG CAPSULE?
Since Aug 23, 2017, the NADAC for ATOMOXETINE HCL 18 MG CAPSULE has ranged from a low of $0.3818 (Sep 23, 2026) to a high of $4.0610 (Sep 13, 2017), with a median of $1.0614 per EA.
Are there cheaper alternatives to ATOMOXETINE HCL 18 MG CAPSULE?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ATOMOXETINE HCL 18 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ATOMOXETINE HCL 18 MG CAPSULE?
ATOMOXETINE HCL 18 MG CAPSULE (NDC 00093354356) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.